Intervention Protocol

You have free access to this content

Antidepressants versus placebo for panic disorder in adults

  1. Giuseppe Guaiana1,*,
  2. Corrado Barbui2,
  3. Debbie Chiodo3,
  4. Andrea Cipriani2,
  5. Simon JC Davies4,
  6. Markus Koesters5

Editorial Group: Cochrane Depression, Anxiety and Neurosis Group

Published Online: 31 JUL 2013

DOI: 10.1002/14651858.CD010676


How to Cite

Guaiana G, Barbui C, Chiodo D, Cipriani A, Davies SJC, Koesters M. Antidepressants versus placebo for panic disorder in adults (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 7. Art. No.: CD010676. DOI: 10.1002/14651858.CD010676.

Author Information

  1. 1

    Western University, Department of Psychiatry, St Thomas, Ontario, Canada

  2. 2

    University of Verona, Department of Public Health and Community Medicine, Section of Psychiatry, Verona, Italy

  3. 3

    King's University College at the University of Western Ontario, Department of Psychology, London, Ontario, Canada

  4. 4

    University of Bristol, School of Social and Community Medicine, Bristol, UK

  5. 5

    Ulm University, Department of Psychiatry ll, Guenzburg, Germany

*Giuseppe Guaiana, Department of Psychiatry, Western University, Saint Thomas Elgin General Hospital, 189 Elm Street, St Thomas, Ontario, N5R 5C4, Canada. Giuseppe.Guaiana@sjhc.london.on.ca. gguaiana@stegh.on.ca.

Publication History

  1. Publication Status: New
  2. Published Online: 31 JUL 2013

SEARCH

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To assess the effects of antidepressants for panic disorder in adults, specifically:

  1. To determine the efficacy of antidepressants in alleviating symptoms of panic disorder, with or without agoraphobia, in comparison to placebo;
  2. To review the acceptability of antidepressants in panic disorder, with or without agoraphobia, in comparison with placebo; and
  3. To investigate the adverse effects of antidepressants in panic disorder, with or without agoraphobia, including the general prevalence of adverse effects, compared to placebo.